Login to Your Account

Teva padding migraine franchise; acquiring Labrys Biologics in potential $825M deal

By Michael Fitzhugh
Staff Writer

Tuesday, June 3, 2014

Teva Pharmaceutical Industries Ltd. is raising its bet in the migraine-fighting market by buying Labrys Biologics Inc. for $200 million up front and up to $625 million in pre-launch milestone payments. The single-compound company's once-monthly injectable migraine prevention drug, LBR-101, could capture $2 billion to $3 billion in sales, according to Teva estimates, adding a lucrative new dimension to its growing portfolio of pain treatments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription